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Introduction
Up to 65% to 80% of the population will suffer from back pain in
their lifetime. Degeneration of the intervertebral disc (IVD) is
thought to be one main factor in the development of back pain and
is responsible for approximately 90% of spine surgery procedures
[1]. Degenerative changes, already observed in the second decade
of life [2, 3], first occur in the nucleus pulposus (NP). Metabolic
activity of the NP cells is modified and leads to a decrease in pro-
teoglycan (PG) content and diminished water retention. Several
factors contribute to the alteration of the cell metabolism, notably
diminished nutrition, cell senescence, mechanical stress and
inflammatory environment [4–7]. Current treatments for back pain
aim at relieving pain but do not treat the causes. Although the ini-
tiating events of disc degeneration are unknown, it has been estab-
lished that degeneration begins with the inability of the NP cells to
maintain matrix homeostasis. Thus, it can be assumed that a cell-
based therapy could be applied to early degenerated disc to
increase matrix synthesis and delay degeneration. This hypothesis
is supported by recent clinical and animal studies, where a cellu-
lar therapy was applied to degenerated discs with variable results
[8–11]. One main key criteria in the success of cellular therapy is
the choice of the source of cells. Cells used for cell-based therapy
need to be readily expanded in vitro and to retain biological activ-
ity for restoring and maintaining organ functions. Due to immuno-
compatibility, autologous cells are usually preferred. However,
disc cells have been shown to have poor proliferation capacity 
in vitro and dedifferentiate into fibroblasts in conventional mono-
layer culture [12–14]. In addition, the IVD offers a limited access
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to retrieve cells for in vitro expansion which is complicated by the
low cellularity of this tissue. In humans, autologous NP cell treat-
ment was investigated at the clinical level in patients suffering
from disc herniation and showed encouraging results although
published data are limited [15]. On the other hand, stem cells are
an alternative cell source for organ regeneration as they have high
self-renewal capacity and can generate multiple cell lineages [16].
Stem cells represent only a small fraction of a tissue cell popula-
tion and thus require an extensive in vitro expansion step. They
were notably able to regenerate the NP in a rabbit model of IVD
degeneration [8, 9, 17]. However, it was impossible to determine
if stem cells could differentiate into NP cells due to the lack of a
defined phenotype. Another potential source of cells for IVD
regeneration is foetal cells. Unlike stem cells, foetal cells are dif-
ferentiated cells with high expansion, regeneration and low
immunogenicity properties [18, 19]. They can be isolated from
foetal tissues, which follow embryonic stage at 9 weeks of devel-
opment. Foetal cell therapies have been clinically applied to several
degenerative conditions such as Parkinson’s [20] or Huntington’s
diseases [21] and to damaged skin [22, 23]. Foetal cell therapy
has also been investigated in spinal cord injury [24, 25], liver dis-
orders, infarctions [26] as well as in bone regeneration [27, 28].
The aim of this study was to assess the feasibility of isolating
foetal cells from foetal spine tissue and to assess their in vitro
matrix production capacity.
Material and methods
Cell isolation
Biopsies for cell isolation were obtained in accordance with the Ethics
Committee of University Hospital in Lausanne (Ethical Protocol 51/01).
Human foetal spinal column tissues (1 cm length, n ! 5) were obtained
from foetuses after voluntary interruption of pregnancy at 12–16 weeks of
gestation. Biopsies were first rinsed with 1% penicillin-streptomycin-
phosphate buffer saline (PBS), cleaned of adjacent tissue and minced in
small pieces. Foetal spine units, composed of one IVD and the two adjacent
vertebrae, were put into culture in Dulbecco’s Modified Eagle’s medium
(DMEM) (Gibco, Switzerland) supplemented with 10% FBS and 100 mM 
L-Glutamine (Gibco) (hereafter referred to as growth medium) at 37"C
under 5% CO2. A cell bank was established from each biopsy as described
in De Buys Roessingh et al. [23] and Quintin et al. [29].
For comparison purpose, NP cells were isolated from adult tissues (n! 3)
obtained from patients undergoing discectomy. Cells were retrieved after
type II collagenase digestion and expanded. Cells were stored frozen in liq-
uid nitrogen at passage 1 or 2. Then cells were thawed, expanded in mono-
layer at passage 3 and used for proliferation and alginate bead culture at
passage 4. Table 1 presents the origin of the cells used in the study.
Cell proliferation
Foetal spine cells and adult NP cells at passage 4 were seeded at 3000 cells
per cm2 in triplicate in 96-well plates with growth medium. At days 0, 3, 7,
10, 14 and 21, 10 #l of CellTiter (Promega, Switzerland) was added to each
well and incubated for 2 hrs at 37"C before measuring optical density at
492 nm with a microplate reader. The assay is based on the formation of
formazan by cell activity after addition of tetrazolium. The amount of for-
mazan formed is measured by optical density at 492 nm and is dependent
on the number of cells and the specific cell activity.
Alginate bead culture
Foetal spine cells and adult NP cells at passage 3 were routinely cultured
in growth medium in monolayer. Cells were trypsinized and suspended in
1.2% alginate solution (Fluka, Switzerland) at the density of 5 million cells
per millilitre. Cell suspension was gently expressed in a dropwise fashion
through a 26 G needle into 102 mM chloride calcium solution. Beads were
left to polymerize for 15 min., washed three times in growth medium, then
cultured in growth medium which had 50 #g/ml of ascorbic acid at 37"C
under 5% O2. Medium was changed twice a week.
Histology of foetal spine tissue and alginate
beads
When possible, parts of the foetal spine tissue biopsy (12–16 weeks) were
flash frozen in liquid nitrogen. Then, 7-#m-thick sections were cut and
used for histology and immunohistochemistry. Paraffin sections of older
foetal spine tissues (19–22 weeks) were provided by the University
Institute of Pathology of Lausanne as numbered and coded tissues.
Alginate beads were fixed in 0.1 M cacodylate buffer, 10 mM calcium chlo-
ride containing 4% paraformaldehyde overnight at 4"C and then washed in
0.1 M cacodylate, barium chloride at 4"C overnight. Then beads were dehy-
drated by successive incubation in 70%, 94%, 100% ethanol and xylol.
Dehydrated beads were embedded in paraffin and 7-#m sections were cut.
Frozen and paraffin sections were stained with alcian blue pH ! 2.5 for 
20 min. and nuclear fast red for 5 min. or with Von Kossa. Sections were
then dehydrated and mounted for light transmission microscopy.
Immunohistochemistry of foetal spine tissue 
and alginate beads
For aggrecan staining, sections were digested with hyaluronidase (Sigma, 
St. Louis, MO, USA) and with pepsin (Sigma) for type II and type I collagen
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Cell name Origin of the cells Age of donor
FS 12w Foetal spine 12 weeks
FS 13w Foetal spine 13 weeks
FS 14w Foetal spine 14 weeks
FS 15w Foetal spine 15 weeks
FS 16w Foetal spine 16 weeks
NP 41y Adult NP 41 years
NP 30y Adult NP 30 years
NP 39y Adult NP 39 years
Table 1 Name and origin of the cells used in the study
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staining. After washing, sections were treated with 0.1% phenylhydrazine
(Merck, Switzerland), washed and blocked in PBS containing triton X-100,
foetal calf serum and normal goat serum. Sections were then incubated with
primary antibodies, aggrecan (1/2000) (Biosource, Nivelles, Belgium), type I
collagen (5 #g/ml) (MP Biomedicals, Solon, OH, USA), type II collagen 
(1 #g/ml) (Chemicon, Temecula, CA, Switzerland) and type X collagen (1/250)
(Sigma) washed and incubated with goat anti-mouse biotinylated secondary
antibody (Vector Laboratories, Burlingame, CA, USA). After washing, sections
were treated with Vectastain ABC kit and DAB revelation system (Victor
Laboratories). Tissue sections and alginate bead sections were, respectively,
counterstained with Papanicolaou and Fast Red, dehydrated and mounted for
microscopic observation.
Glycosaminoglycan (GAG) and DNA analysis
After 28 days of culture in alginate beads in growth medium with 50 #g/ml
of ascorbic acid, foetal spine cells and adult NP cells were analysed for
GAG and DNA content.
Ten beads were digested in 2.3 U/ml of papain in 100 mM Na2HPO4, 
10 mM ethylenediaminetetraacetic acid, 10 mM cysteine HCl at pH to 6.5
at 60"C for 14 hrs. The digest solution was assayed for GAG and DNA
quantification. GAG content (#g/ml) was measured following the method
of Enobakhare et al. [30]. Two hundred microlitres of DMMB solution at 
pH ! 1.5 was mixed to 20 #l of digested beads. Absorbance was read at
595 nm and GAG concentrations were calculated by using a standard curve
of chondroitin sulphate C (Sigma). DNA concentration (#g/ml) of digested
beads was measured using Hoechst 33258 and calf thymus DNA as a stan-
dard. Then GAG/DNA ratio was calculated by normalizing the GAG concen-
tration to DNA concentration for each sample.
RNA extraction and reverse transcription
Beads were dissolved in 55 mM sodium citrate and 30 mM ethylenedi-
aminetetraacetic acid for 10 min. at 37"C. Cells were centrifuged and the
cell pellet recuperated. RNA was extracted from the cell pellet using the
Trizol method. RNA quantity and quality was assessed with Agilent
Bioanalyser 2100 (Agilent Technologies, Waldbronn, Germany). One
microgram of RNA was reverse transcribed using the Taqman Universal
PCR kit with random hexamers (Applied Biosystems, Branchburg, NJ,
USA) following manufacturer instructions. Primers for Glyceraldehyde 
3-Phosphate dehydrogenase (GAPDH), SOX-9, RUNX-2, aggrecan, type I,
type II and type X collagens genes were designed using the PrimerExpress
software. Primer sequences are presented in Table 2. PCR reactions were
performed with the UniprimerR technology (Intergen Discovery Products,
Purchase, NY, USA) performed in a total volume of 25 #l (5 #l of first
strand DNA, 12.5 #l of TaqMan Universal PCR Master Mix (Applied
Biosystems), and 7.5 #l of the primers working solution with the ABI
Prism 7700 (Applied Biosystems). Primers working solution included for-
ward primer with an additional sequence of 18 bp added to the 5$ end,
reverse primer and Amplifluor Uniprimer (Intergen Discovery Products).
Thermal cycle conditions were 50"C 2 min., 95"C 10 min., then 50 cycles
at 95"C 15 sec., 60"C 1 min. Measurements were performed in duplicates
for each sample and mean of the Cts was used for calculation. For each
sample, target and housekeeping gene expressions were calculated using
the 2%Ct formula with GAPDH as housekeeping gene. Then the target gene
expression normalized to the housekeeping gene expression was calcu-
lated for each sample by using the 2%&Ct method.
Results
Histology and immunohistochemistry of foetal
spine tissue
Alcian blue sections of foetal spine showed that IVD were already
differentiated tissue where the gelly NP and fibrous annulus fibro-
sus (AF) were already present in the 15-week tissue donor (Fig. 1A).
The NP contained notochordal cells in clusters with a polysaccha-
ride-rich ECM (Fig. 1B). Fibres with fibroblastic cells were present
in the outer AF (Fig. 1D) whereas the inner AF was more a hyaline
structure with chondrocytic cells (Fig. 1C). Primary ossification
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Gene Forward primer Reverse primer
GAPDH CCACCCATGGCAAATTCC TGGGATTTCCATTGATGACAAG
Aggrecan AGTATCATCAGTCCCAGAATCTAGCA AATGCAGAGGTGGTTTCACTCA
Type II collagen GGGCAATAGCAGGTTCACGTA CGATAACAGTCTTGC CCCACTT
Type I collagen CTCCTCAAGGGCTCCAACG CATCGACAGTGACGCTGTAGGT
Type X collagen CAGATTTGAGCTATCAGACCAACAA AAATTCAAGAGAGGCTTCACATACG
SOX-9 AGACCTTTGGGCTGCCTTAT TAGCCTCCCTCACTCCAAGA
(source: http://medgen.ugent.be/rtprimerdb) (source: http://medgen.ugent.be/rtprimerdb)
RUNX-2 AACCCACGAATGCACTATCCA CGGACATACCGAGGGACATG
Table 2 Sequences of the primers used in this study. An additional sequence of 18 bp was added to the 5$ end of forward primer to be used with
the Amplifluor Uniprimer system
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Fig. 1 Alcian blue staining (A, B, C, D)
and aggrecan (E, F, G), immunostainig of
a 15-week intervertebral disc (A),
nucleus pulposus (B, E), inner annulus
fibrosus (AF) (C, F) and outer annulus
fibrosus (D, G). Scale ! 100 #m.
Fig. 2 Type II collagen (A, B, C) and type
I collagen (D, E, F) immunostainig of a
15-week intervertebral disc (A), nucleus
pulposus (A, D), inner annulus fibrosus
(AF) (B, E) and outer annulus fibrosus 
(C, F). Alcian blue (G, I) and Von Kossa
(H, J) staining of the ossification centre
of a 12-week old (G, H) and 20-week old
(I, J) foetal vertebrae. Scale ! 100 #m.
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centre of body vertebrae could be observed in the five samples but
with variable degree of maturation (Fig. 2G–J). In the youngest
sample (12 weeks), hypertrophic chondrocytes could be observed
but without any blood invasion. However a small area of calcifica-
tion can be identified by Von Kossa staining (Fig. 2G and H). In
older tissues, calcification zone with blood marrow invasion could
be observed (Fig. 2I and J). Aggrecan was present in the NP as
well as in the inner and outer AF (Fig. 1E–G). Type II collagen was
also present in the NP and inner AF (Fig. 2A and B). In contrast,
type I collagen was present in the outer annulus but gradually dis-
appeared towards the NP (Fig. 2D–F).
Cell proliferation
Foetal and adult cells were cultured in monolayer in growth
medium at an initial density of 3000 cell/cm2. From the third day
of culture, foetal spine cells started to proliferate more rapidly
than adult NP cells (Fig. 3A). From each foetal tissue donation, a
cell bank of foetal spine cells at passage 2 was established and
was composed of around 2000 vials of 5 million cells (Fig. 3B).
For comparison, average yield of adult NP cells ranged from 5 to
10 million cells at passage 0. By monolayer expansion of cell
bank of 200 to 400 million cells at passage 2 can be established for
each adult donor.
Histology of foetal and adult cells in alginate beads
Foetal cells encapsulated in alginate were present as single cells 
or in clusters. Clusters of cells were only observed in the FS 14w,
FS 15w and FS 16w (Fig. 4A). Production of sulphated gly-
cosaminoglycan (sGAG), stained in intense blue by alcian 
blue, was observed around clusters of cells as well as isolated
cells. However, some cells were not surrounded by alcian blue
stained matrix.
Gene expression and immunohistochemistry 
of foetal cells in alginate beads
Foetal cells were culture for 28 days in alginate beads at 5 million
cell/ml in growth media supplemented with ascorbic acid. Cells
were collected at 7, 14 and 28 days of culture to assess gene
expression of the transcription factors SOX-9, RUNX-2 (Fig. 5)
and matrix component aggrecan, type II, type I and type X colla-
gens (Fig. 6). Individual values are presented as large donor to
donor variations were observed.
Cells from two donors (FS 14w and FS 15w) showed a large
increase in SOX-9 expression and a decrease in RUNX-2 expres-
sion. One donor’s cells (FS 16w) showed an inverse pattern with 
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Fig. 3 (A) Proliferation
curve of foetal spine cells
and adult nucleus pulposus
(NP) in monolayer at pas-
sage 4 during 21 days.
Mean ' 1S.D. of five foetal
spine cells (!) and three
adult NP cells ("). (B)
Establishment of a foetal
spine cell bank from one
foetal spine tissue donation.
Cells were isolated from
spinal unit (one interverte-
bral disc and two vertebrae)
and amplified in monolayer.
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a decrease in SOX-9 and an increase in RUNX-2 expression.
Whereas another donor’s cells (FS 12w) showed a decrease in
both transcription factors and the last donor’s cells (FS 13w)
showed a stable SOX-9 expression accompanied by a decrease in
RUNX-2. Aggrecan gene expression was stable in four cell donors
and was increased in only one sample (FS 14w) (Fig. 6A).
However, aggrecan protein was detected in all the five cell donors
but with high variation between donors (Fig. 4B). Type II collagen
expression was largely increased between 14 and 28 days of 
culture in all the five cell donors (Fig. 6B) but staining was hetero-
geneous between donors (Fig. 7A). High staining was observed in
the two cell donors with the highest increase in gene expression 
(FS 14w, FS 15w). These cells also showed a heterogeneous 
pattern for type II collagen expression. Some cells did not express
type II collagen at all whereas neighbouring clusters or isolated cells
were highly positive. Time course of type I collagen gene expression
was variable between donors (Fig. 6C). It moderately increased in
two cell donors (sixfold for FS 15w, twofold for FS 16w) and low
level of the protein was detected in the matrix (Fig. 7B). Type I col-
lagen remained stable in the 12w, 13w and 14w donors where very
low protein stain could be observed. When measuring the ratio of
type II to type I gene expression, it increased during the culture
period for the five cell donors (Fig. 6E). Type X collagen gene
expression decreased during the culture period in four cell donors
and remained stable in the older donor cells (FS 16w) (Fig. 6D). In
these cells, type X collagen was strongly detected (Fig. 7C). In the
case of adult NP cells, staining of aggrecan, type II, I and X collagen
was very low to absent (Figs. 4 and 7).
GAG and DNA content
To measure the quantity of sGAG produced by the cells, GAG was
quantified by DMMB and normalized to DNA content of the beads.
Adult cells entrapped in alginate beads tended to show a slightly
higher DNA content than foetal cells (Fig. 8). Two foetal cell
donors (FS 12w and FS 16w) tended to have a smaller DNA con-
tent than the three other foetal cell donors. Two foetal cell donors
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Fig. 4 (A) Alcian blue staining and (B) aggrecan immunostaining of foetal spine cells and adult nucleus pulposus cells after 28 days of culture in algi-
nate beads. Arrows point to alcian blue stained matrix.
Fig. 5 (A) SOX-9 and (B) RUNX-2 gene expression was measured by real-time PCR at 7, 14 and 28 days of culture in alginate beads. Target gene expres-
sions were normalized to housekeeping gene GAPDH by using the 2%&Ct method.
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(FS 14w and FS 15w) showed 3.6 times higher GAG content than
adult NP cells. The three remaining foetal cell donors had a GAG
content similar to the one of the adult cells. Results were similar
when the GAG content was normalized to the DNA content. In
addition, GAG/DNA ratio correlated well with the intensity of the
alcian blue stain. The two samples showing an intense stain, 
FS 14w and FS 15w gave the highest ratio of GAG to DNA.
Discussion
This study presents the spontaneous matrix production of human
foetal spine cells in alginate beads. The hypothesis of cell regen-
eration of the NP has strengthened with publications of NP regen-
eration by autologous, allogenous or stem cells transplantation in
animal models [8, 11, 31–33]. One of the main criteria for its
translation into the clinic is the choice of the cells. According to
previous work performed with foetal skin and foetal bone cells, we
speculate that foetal IVD could also be a good source of cells for
NP regeneration. As foetal tissue donation after voluntary interrup-
tion of pregnancy is considered as an organ donation, it 
follows ethical rules applied to organ donation. Benefits of foetal
cell therapy reside in the fact that it is possible to develop exten-
sive cell banks using only one foetal organ donation. We first
investigated the histology of foetal spine tissue from which foetal
cells were isolated. IVD structures, i.e. NP, inner AF, outer AF could
be histologically identified. Aggrecan was present in the whole
IVD. Type II collagen was present in NP and inner AF whereas type I
collagen was only present in the outer AF. These results are in
agreement with previous studies on the matrix composition of
foetal spine [34–37] and are similar to that of adult IVD. One main
difference is the presence of notochordal cells as the only cells
present in the foetal NP. In a first attempt, we tried to establish
separate cultures of pure NP and AF cells. Due to the small size 
(1 mm thickness) and the very soft consistency of the foetal spine,
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Fig. 6 (A) Aggrecan, (B) type II collagen, (C) type I collagen and 
(D) type X collagen gene expression was measured by real-time PCR
at 7, 14 and 28 days of culture in alginate beads. Target gene expres-
sions were normalized to housekeeping gene GAPDH by using the
2%&Ct method. (E) Ratio of type II to type I collagen. 
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it was not feasible to isolate IVD from the adjacent vertebrae. In
addition, there is no specific marker available to assess the purity
of the cell population obtained. Hence, we have chosen to estab-
lish cell culture from whole spine units (one IVD and the two adja-
cent vertebrae). Notochordal cells were observed in the culture
media but they did not proliferate neither were adherent. As a
result, our foetal spine cell cultures are mixed cultures of cells
coming from disc annulus and vertebrae. As consistency of cell
cultures to be used for tissue-engineering project is of primary
importance, stability of the foetal spine cell phenotype was
checked at passages 4, 6 and 8 by microscopic observation of cell
morphology and by FACS analysis of HIF-1 and galectin-3 expres-
sion (data not shown) [29]. From the histological analysis, foetal
vertebrae between 12 and 16 weeks were still cartilaginous tissue
but ossification centres could be identified. In the 12-week spine,
ossification centre could be observed but with very small area 
of calcified region, whereas in the 15-week foetal spine, bone for-
mation and calcification could be observed. Further investigation
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Fig. 8 (A) GAG (#g/ml), (B) DNA (#g/ml) and (C)
GAG/DNA (#g/#g) ratio measured in foetal spine cells
and adult nucleus pulposus cells after 28 days of culture
in alginate beads.
Fig. 7 (A) type II collagen, (B) type I collagen and (C) type X collagen immunostaining of foetal spine cells and adult nucleus pulposus cells after 
28 days of culture in alginate beads. Asterisk indicates non-stained cells.
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performed on older foetal spine (19–22 weeks of gestation)
showed presence of calcified area in the vertebrae, which were not
observed in younger samples. A recent study performed with MRI
on foetal lumbar spine showed that the lumbar vertebral area of
ossification appears around the age of 14–15 weeks [38], which
confirms our histological observations. These data indicate that
our cell populations may contain hypertrophic chondrocytes, rais-
ing the risk of endochondral bone formation.
In vitro assessment of matrix production by chondrocyte cells
requires a three-dimension system such as alginate beads.
Alginate has been shown to be an appropriate matrix to support
chondrogenesis of articular cartilage [39–41], IVD [42, 43] and
stem cells [44–46]. Alginate beads also support endochondral
[47, 48] and osteogenic [49, 50] differentiation. Mechanisms of
chondrogenic differentiation in alginate beads have yet not been
elucidated. They do not likely rely on specific alginate-cell interac-
tion as alginate does not promote protein adsorption [51] but
more likely on cell cytoskeleton reorganization [52]. So we
assumed that alginate bead culture of foetal spine cells would
reflect the spontaneous activity of the cells in a three-dimensional
system. Only ascorbic acid was added to the media as it is neces-
sary for collagen production [53]. Aggrecan could be detected in
all the five samples but to a various extent across donors.
Intensity of aggrecan staining correlated well with the GAG/DNA
ratio, indicating that aggrecan is one of the main sulphated PG
produced by these cells. In addition, the GAG production of the
higher producing foetal cells was much higher than that of adult
NP cells cultured in the same conditions. As the DNA content was
fairly similar in all samples, the GAG production is likely due to a
high cellular activity rather than to a higher number of cells.
Difference in donors was even more marked in type II collagen
production. Age of the donors may explain this large variation.
However, due to the low number of samples, it cannot be excluded
that other factors, such as foetal tissue quality and cell isolation
procedure play a role in sample variation.
In the same way, cells from a same donor were also heteroge-
neous for collagen type II staining, likely explained by the mix pop-
ulations of cells in our foetal spine cells. It can be speculated that
cells which do not produce type II collagen are derived from the
outer AF, which is poor in type II collagen. It was not possible to
assess the origin of the cells due to the lack of specific marker. We
also investigated type I collagen as its expression is a usual result
of chondrocyte dedifferentiation and the ratio of collagen II to I can
be used as a marker of differentiation [54]. This ratio increased for
all donors during culture in alginate beads indicating that cells
were differentiating towards a chondrocyte phenotype.
Confirmation of these results by increase in SOX-9 gene expres-
sion was only observed for two donors (FS 14w and 
FS 15w). As previously mentioned, the presence of vertebrae cells
raises the risk of endochondral ossification. Thus RUNX-2 gene
expression and type X collagen production were measured during
the alginate culture [55]. Endochondral markers were very lowly
expressed by four cell donors. Only the older donor (FS 16w)
showed type X collagen protein production. This result could be
explained by a more advanced stage of mineralization of the ver-
tebrae leading to the majority of chondrocytes already directed in
the hypertrophy pathway. Confirmation of the correlation between
age of the foetal tissue donor and endochondral ossification
require a larger number of donors. Nevertheless, these results
indicate cells isolated from foetal spine can have spontaneous car-
tilage matrix synthesis properties. In this study, adult NP cells
showed very low matrix synthesis capacity. Culture conditions of
NP adult cells were not optimized as addition of growth factors
such as BMP-2, BMP-12, OP-1, TGF-(s can partially restore
matrix production after monolayer expansion [56–59]. However,
the aim of the study was to observe spontaneous behaviour of
cells as avoiding the use of growth factors for cell therapy could
increase biosafety and could reduce cost of the final product. The
use of animal products (bovine serum, trypsin) in cell culture to
be used for clinical trials can hardly be avoided and represents a
risk of contamination of the final product. Any animal products
used should be virus tested and transmissible spongiform
encephalopathies certified [60]. Countries with no reported cases
of bovine spongiform encephalopathies, like New Zealand or
Australia, are interesting source of serum for research and clinical
purposes [61]. Otherwise, a traceability of each serum bottle to be
used for cell culture for clinical usage is required. Up to now, the
most attractive source of cells for NP regeneration is stem cells.
Chondrogenic differentiation of stem cell requires the use of
growth factors such as TGF-(s, which induce type X collagen pro-
duction and drive chondrocyte hypertrophy [45, 48, 64–68]. In
addition, stem cell cultures require the use of growth factors in
order to maintain their stem cell property. For a clinical applica-
tion, the use of growth factors is a potential risk for the final prod-
uct biosafety and increases the cost for establishing a cell bank. If
differentiated cells have to be used for cell treatment of the NP, this
problem could be alleviated by the use of foetal spine cells, which
matrix production does not require the use of growth factors and
which escape from hypertrophy. If non-differentiated cells are to
be used, the fate of these cells in the degenerated disc will depend
on many uncontrolled environmental factors such as nutrition,
mechanical loading, inflammation and interaction with endogenous
cells. These factors will also have high impact on the long term fate
of pre-differentiated cells. In both cases, the success of NP regen-
eration relies on the adaptation of the cells to such a complex envi-
ronment, and this can only be assessed by in vivo trials.
In conclusion, we have shown that after a careful selection of
the right donor, a foetal spine cell bank can be established, offering
security and reproducibility for a clinical cell therapy. These cells
showed high levels of in vitro matrix synthesis properties com-
pared to adult NP cells. The next step of the cell characterization
will be to test the in vivo efficacy of these cells in an appropriate
animal model.
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